News is a concise, evidence-aware briefing on what matters in healthcare—new trials, guideline changes, drug approvals, device safety, and health-policy shifts.
CSL Seqirus, the vaccine unit of Australian biotech CSL, signed a pact to provide Saudi Arabia with cell-based influenza shots and to help establish its production in-country. The move comes as part
Eli Lilly has revealed a plan to spend $1.2 billion to upgrade its plant in Carolina, Puerto Rico. The investment will add 100 manufacturing jobs and bolster the company’s capacity to produce
The FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining
The FDA slammed generics maker Hetero with a Form 483 after an inspection of one of its warehouses in India uncovered flying birds, skittering lizards and roaming cats, among a host of
CDMO Catalent has unveiled a new corporate brand, which keeps the company’s moniker the same while trading in the simple blue-against-white lettering of its previous logo with a pair of intersecting, speech
The company expects sales in the second half of the year to outpace those from the first and reiterated its annual revenue guidance, projecting growth between 20% and 21% for all of
Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and
Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month that its owner was seeking a sale.
Nephron Pharmaceuticals’ manufacturing facility in West Columbia, South Carolina, is still running afoul of the FDA. In its most recent Form 483 report, the agency has cited several problems that were evident